Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study

 

Anidulafungin

Micafungin

P

(n = 30)

(n = 33)

On admission

 Age (years)

59 (20)

62 (20)

0.36

 Gender (male)a

19 (63)

26 (79)

0.18

 APACHE II score

26 (10)

23 (8)

0.13

 SOFA score

10 (9)

9 (3)

0.63

 Reasons of ICU admissiona

  

0.14

  Suspected sepsis

9 (30)

11 (33)

 

  Respiratory failure

2 (7)

6 (19)

 

  Renal failure

1 (3)

0 (0)

 

  Liver failure

4 (13)

0 (0)

 

  CPR

2 (7)

2 (6)

 

  Shock

5 (17)

3 (10)

 

  Postoperative

7 (23)

11 (34)

 

At start of echinocandin

 Risk factors for invasive candidiasisa

 Neutropenia

3 (10)

2 (6)

0.57

 Broad spectrum antibiotics

18 (60)

15 (45)

0.25

 Immunosuppression

4 (13)

3 (9)

0.60

 Steroids

16 (53)

12 (36)

0.18

 TPN

4 (13)

11 (33)

0.07

 Recent Surgery

8 (27)

15 (45)

0.13

 DM II

11 (37)

7 (21)

0.18

 Malignancy

5 (17)

11 (33)

0.13

 Transplant

5 (17)

4 (12)

0.61

 CVVH

19 (63)

7 (21)

0.001

 CVC

29 (97)

29 (88)

0.20

 Mechanical ventilation

27 (90)

32 (97)

0.26

Duration between admission and start echinocandin (days)

3 (4)

2 (2)

0.17

  1. Numbers (percentage) aor median (interquartile range), where appropriate
  2. List of abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, CPR cardiac pulmonary resuscitation, CVVH continuous venovenous haemofiltration, CVC central venous catheter, DM II diabetes mellitus type II, ICU intensive care unit, TPN total parenteral nutrition